VERTEX PHARMACEUTICALS INC / MA Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2019-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2019-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2019-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2020 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2019 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2018 was -$9.79M.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2017 was -$171.85M, a 713.29% decline from fiscal 2016.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-11 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $0.00 derived: sum of 3 quarters · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | |
| 2019-09-30 | $0.00 10-Q · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $0.00 10-Q · filed 2019-10-31 | -$25.43M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | -$25.43M derived: sum of 3 quarters · filed 2021-02-11 | -$25.72M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | -$25.43M derived: sum of 2 quarters · filed 2021-02-11 | -$25.72M derived: sum of 3 quarters · filed 2021-02-11 | -$26.83M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | -$25.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$25.72M derived: sum of 2 quarters · filed 2021-02-11 | -$26.83M derived: sum of 3 quarters · filed 2021-02-11 | -$9.79M 10-K · filed 2021-02-11 | |
| 2018-09-30 | -$290.00K 10-Q · filed 2019-10-31 | -$1.40M derived: sum of 2 quarters · filed 2019-10-31 | $15.64M 10-Q · filed 2019-10-31 | $17.14M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | -$1.11M 10-Q · filed 2019-08-01 | $15.93M 10-Q · filed 2019-08-01 | $17.43M derived: sum of 3 quarters · filed 2020-02-13 | -$170.89M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | $17.04M 10-Q · filed 2019-05-01 | $18.54M derived: sum of 2 quarters · filed 2020-02-13 | -$169.78M derived: sum of 3 quarters · filed 2020-02-13 | -$156.60M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2017-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$186.81M derived: sum of 2 quarters · filed 2020-02-13 | -$173.64M derived: sum of 3 quarters · filed 2020-02-13 | -$171.85M 10-K · filed 2020-02-13 | |
| 2017-09-30 | -$188.31M 10-Q · filed 2018-10-25 | -$175.14M derived: sum of 2 quarters · filed 2018-10-25 | -$173.35M 10-Q · filed 2018-10-25 | -$178.54M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | $13.17M 10-Q · filed 2018-07-26 | $14.96M 10-Q · filed 2018-07-26 | $9.78M derived: sum of 3 quarters · filed 2019-02-13 | $9.08M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-03-31 | $1.79M 10-Q · filed 2018-04-27 | -$3.39M derived: sum of 2 quarters · filed 2019-02-13 | -$4.09M derived: sum of 3 quarters · filed 2019-02-13 | $24.28M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2016-12-31 | -$5.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$5.88M derived: sum of 2 quarters · filed 2019-02-13 | $22.49M derived: sum of 3 quarters · filed 2019-02-13 | $28.02M 10-K · filed 2019-02-13 | |
| 2016-09-30 | -$696.00K 10-Q · filed 2017-10-30 | $27.68M derived: sum of 2 quarters · filed 2017-10-30 | $33.21M 10-Q · filed 2017-10-30 | $32.27M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-06-30 | $28.37M 10-Q · filed 2017-07-28 | $33.90M 10-Q · filed 2017-07-28 | $32.97M derived: sum of 3 quarters · filed 2018-02-15 | $34.30M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-03-31 | $5.53M 10-Q · filed 2017-04-28 | $4.59M derived: sum of 2 quarters · filed 2018-02-15 | $5.92M derived: sum of 3 quarters · filed 2018-02-15 | -$26.22M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2015-12-31 | -$938.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $395.00K derived: sum of 2 quarters · filed 2018-02-15 | -$31.75M derived: sum of 3 quarters · filed 2018-02-15 | -$31.85M 10-K · filed 2018-02-15 | |
| 2015-09-30 | $1.33M 10-Q · filed 2016-10-31 | -$30.81M derived: sum of 2 quarters · filed 2016-10-31 | -$30.91M 10-Q · filed 2016-10-31 | -$35.10M derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-06-30 | -$32.14M 10-Q · filed 2016-08-01 | -$32.24M 10-Q · filed 2016-08-01 | -$36.43M derived: sum of 3 quarters · filed 2017-02-23 | -$36.43M derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-03-31 | -$98.00K 10-Q · filed 2016-05-03 | -$4.29M derived: sum of 2 quarters · filed 2017-02-23 | -$4.29M derived: sum of 3 quarters · filed 2017-02-23 | -$4.29M derived: sum of 4 quarters · filed 2017-02-23 | |
| 2014-12-31 | -$4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$4.19M derived: sum of 2 quarters · filed 2017-02-23 | -$4.19M derived: sum of 3 quarters · filed 2017-02-23 | -$4.19M 10-K · filed 2017-02-23 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | $13.69M derived: sum of 4 quarters · filed 2016-02-16 | |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-04 | $0.00 10-Q · filed 2015-08-04 | $13.69M derived: sum of 3 quarters · filed 2016-02-16 | $9.16M derived: sum of 4 quarters · filed 2016-02-16 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-04 | $13.69M derived: sum of 2 quarters · filed 2016-02-16 | $9.16M derived: sum of 3 quarters · filed 2016-02-16 | $4.61M derived: sum of 4 quarters · filed 2016-02-16 | |
| 2013-12-31 | $13.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $9.16M derived: sum of 2 quarters · filed 2016-02-16 | $4.61M derived: sum of 3 quarters · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | -$242.52M 10-K · filed 2014-02-11 |
| 2013-09-30 | -$4.53M 10-Q · filed 2013-11-07 | -$9.08M derived: sum of 2 quarters · filed 2014-07-31 | -$13.69M 10-Q · filed 2013-11-07 | -$71.51M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-06-30 | -$4.55M 10-Q · filed 2014-07-31 | -$9.16M 10-Q · filed 2014-07-31 | -$66.98M derived: sum of 3 quarters · filed 2015-02-13 | -$35.91M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-03-31 | -$4.61M 10-Q · filed 2014-05-05 | -$62.44M derived: sum of 2 quarters · filed 2015-02-13 | -$31.36M derived: sum of 3 quarters · filed 2015-02-13 | -$897.00K derived: sum of 4 quarters · filed 2015-02-13 | |
| 2012-12-31 | -$57.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$26.75M derived: sum of 2 quarters · filed 2015-02-13 | $3.71M derived: sum of 3 quarters · filed 2015-02-13 | $0.00 10-K · filed 2015-02-13 | $55.90M 10-K · filed 2013-03-01 |
| 2012-09-30 | $31.08M 10-Q · filed 2013-11-07 | $61.54M derived: sum of 2 quarters · filed 2013-11-07 | $57.83M 10-Q · filed 2013-11-07 | $87.34M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-06-30 | $30.46M 10-Q · filed 2013-08-02 | $26.75M 10-Q · filed 2013-08-02 | $56.26M derived: sum of 3 quarters · filed 2014-02-11 | $63.60M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-03-31 | -$3.71M 10-Q · filed 2013-05-08 | $25.80M derived: sum of 2 quarters · filed 2014-02-11 | $33.14M derived: sum of 3 quarters · filed 2014-02-11 | $7.89M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2011-12-31 | $29.51M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $36.85M derived: sum of 2 quarters · filed 2014-02-11 | $11.61M derived: sum of 3 quarters · filed 2014-02-11 | $11.61M 10-K · filed 2014-02-11 | |
| 2011-09-30 | $7.34M 10-Q · filed 2012-11-06 | -$17.91M derived: sum of 2 quarters · filed 2012-11-06 | -$17.91M 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | -$25.25M 10-Q · filed 2012-08-08 | -$25.25M 10-Q · filed 2012-08-08 | |||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |